Detalles de la búsqueda
1.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Lancet
; 397(10274): 592-604, 2021 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581821
2.
Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise.
J Cancer Educ
; 36(5): 1005-1013, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130672
3.
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(6): 822-835, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27132212
4.
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Int J Cancer
; 139(1): 177-86, 2016 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26891420
5.
A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Oncologist
; 21(1): 7-15, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26668251
6.
Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
Support Care Cancer
; 24(1): 395-400, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26092233
7.
Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
Support Care Cancer
; 24(12): 4913-4920, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27501966
8.
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 171-9, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25547219
9.
Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer.
Anticancer Drugs
; 26(10): 1061-8, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26295868
10.
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Gastric Cancer
; 18(3): 476-84, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25038874
11.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(1): 59-68, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24331154
12.
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Breast Cancer Res Treat
; 137(2): 471-82, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23239151
13.
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
BMC Cancer
; 13: 386, 2013 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-23945072
14.
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.
J Clin Oncol
; 41(11): 1957-1964, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018920
15.
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis.
Clin Cancer Res
; 22(13): 3172-81, 2016 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26851187
16.
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Clin Cancer Res
; 22(12): 2848-54, 2016 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26813359
17.
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
Mol Cancer Ther
; 15(9): 2251-8, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27325685
18.
Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.
Springerplus
; 4: 316, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26155455
19.
Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.
Med Oncol
; 32(6): 623, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25966791
20.
Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.
Clin Breast Cancer
; 14(2): 101-8, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24485296